Human Papillomavirus-Associated Oropharyngeal Cancer: Global Epidemiology and Public Policy Implications

被引:10
作者
Ndon, Sifon [1 ]
Singh, Amritpal [2 ]
Ha, Patrick K. [1 ]
Aswani, Joyce [3 ]
Chan, Jason Ying-Kuen [4 ]
Xu, Mary Jue [1 ]
机构
[1] Univ Calif San Francisco, Dept Otolaryngol Head & Neck Surg, San Francisco, CA 94115 USA
[2] Univ Calif San Francisco, Sch Med, San Francisco, CA 94143 USA
[3] Univ Nairobi, Dept Surg, Nairobi 00100, Kenya
[4] Chinese Univ Hong Kong, Dept Otorhinolaryngol Head & Neck Surg, Hong Kong, Peoples R China
关键词
human papillomavirus; oropharyngeal cancer; gender-neutral vaccination policy; ORAL HUMAN-PAPILLOMAVIRUS; VACCINE INTRODUCTION; HPV VACCINATION; NECK-CANCER; YOUNG-ADULTS; PREVALENCE; HEAD; INCOME; POPULATION; AUSTRALIA;
D O I
10.3390/cancers15164080
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Global trends in human papillomavirus (HPV)-associated head and neck cancers (HNC), specifically in the oropharynx subsite, have been dynamically changing, leading to new staging and treatment paradigms. Epidemiologic studies have noted regional variations in HPV-associated oropharyngeal squamous cell carcinoma (OPSCC). While HPV vaccination remains the main preventative approach, vaccination policy in relation to gender neutrality is heterogeneous and particularly sparse in low- and middle-income countries, where the burden of global cancer cases and HPV-associated HNC are not well-characterized in certain regions. This review summarizes the existing literature on regional variations of HPV-associated OPSCC and gender-neutral vaccine policies. Based on available data, the incidence of HPV-associated OPSCC is highest in North America, Europe, and Oceania. As of 2022, 122 of 195 (63%) World Health Organization (WHO) member states had incorporated HPV vaccinations nationally; of these, 41 of 122 (34%) member states have introduced gender-neutral vaccine coverage. Future research is needed to describe continued evolving trends in HPV-associated OPSCC, understand underlying risk factors leading to regional variation in disease, and implement gender-neutral policy more broadly.
引用
收藏
页数:14
相关论文
共 80 条
[1]  
A Phase 3, 2023, International, Multi-center, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Study the Efficacy, Immunogenicity, and Safety of the 9vHPV Vaccine, a Multivalent L1 Virus-like Particle Vaccine, in the Prevention of Oral Persistent Infection With HPV Types 16, 18, 31, 33, 45, 52, or 58 in Adult Males, 20 to 45 Years of Age
[2]   Prophylactic Human Papillomavirus Vaccination: From the Origin to the Current State [J].
Akhatova, Ayazhan ;
Azizan, Azliyati ;
Atageldiyeva, Kuralay ;
Ashimkhanova, Aiymkul ;
Marat, Aizada ;
Iztleuov, Yerbolat ;
Suleimenova, Assem ;
Shamkeeva, Saikal ;
Aimagambetova, Gulzhanat .
VACCINES, 2022, 10 (11)
[3]   HPV Detection in Head and Neck Squamous Cell Carcinomas: What Is the Issue? [J].
Augustin, Jeremy Gbenakpon ;
Lepine, Charles ;
Morini, Aurelien ;
Brunet, Anais ;
Veyer, David ;
Brochard, Camille ;
Mirghani, Haitham ;
Pere, Helene ;
Badoual, Cecile .
FRONTIERS IN ONCOLOGY, 2020, 10
[4]  
Baisley K, 2022, LANCET GLOB HEALTH, V10, pE1485, DOI 10.1016/S2214-109X(22)00306-0
[5]  
Barnabas Ruanne V, 2022, NEJM Evid, V1, pEVIDoa2100056, DOI 10.1056/EVIDoa2100056
[6]   Achieving high coverage in Rwanda's national human papillomavirus vaccination programme [J].
Binagwaho, Agnes ;
Wagner, Claire M. ;
Gatera, Maurice ;
Karema, Corine ;
Nutt, Cameron T. ;
Ngabo, Fidele .
BULLETIN OF THE WORLD HEALTH ORGANIZATION, 2012, 90 (08) :623-628
[7]   Experiences of operational costs of HPV vaccine delivery strategies in Gavi-supported demonstration projects [J].
Botwright, Siobhan ;
Holroyd, Taylor ;
Nanda, Shreya ;
Bloem, Paul ;
Griffiths, Ulla K. ;
Sidibe, Anissa ;
Hutubessy, Raymond C. W. .
PLOS ONE, 2017, 12 (10)
[8]   Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries [J].
Brisson, Marc ;
Kim, Jane J. ;
Canfell, Karen ;
Drolet, Melanie ;
Gingras, Guillaume ;
Burger, Emily A. ;
Martin, Dave ;
Simms, Kate T. ;
Benard, Elodie ;
Boily, Marie-Claude ;
Sy, Stephen ;
Regan, Catherine ;
Keane, Adam ;
Caruana, Michael ;
Nguyen, Diep T. N. ;
Smith, Megan A. ;
Laprise, Jean-Francois ;
Jit, Mark ;
Alary, Michel ;
Bray, Freddie ;
Fidarova, Elena ;
Elsheikh, Fayad ;
Bloem, Paul J. N. ;
Broutet, Nathalie ;
Hutubessy, Raymond .
LANCET, 2020, 395 (10224) :575-590
[9]   Population-based HPV vaccination programmes are safe and effective: 2017 update and the impetus for achieving better global coverage [J].
Brotherton, Julia M. L. ;
Bloem, Paul N. .
BEST PRACTICE & RESEARCH CLINICAL OBSTETRICS & GYNAECOLOGY, 2018, 47 :42-58
[10]   HPV vaccination introduction worldwide and WHO and UNICEF estimates of national HPV immunization coverage 2010-2019 [J].
Bruni, Laia ;
Saura-Lazaro, Anna ;
Montoliu, Alexandra ;
Brotons, Maria ;
Alemany, Laia ;
Diallo, Mamadou Saliou ;
Afsar, Oya Zeren ;
LaMontagne, D. Scott ;
Mosina, Liudmila ;
Contreras, Marcela ;
Velandia-Gonzalez, Martha ;
Pastore, Roberta ;
Gacic-Dobo, Marta ;
Bloem, Paul .
PREVENTIVE MEDICINE, 2021, 144